From the CEO
As the mining boom sputters out, Australia is taking a long-overdue look at ways to improve its competitiveness in a cut-throat global marketplace.
The global business environment is changing rapidly. The economic rise and technological advances of many Asian nations may open up new markets for Australia, but it is also introducing new competitors.
News and Updates
Medicines Australia has put forward its recommendations for consideration in its submission to the Therapeutic Goods Administration’s (TGA) Expert Review of Medicines and Medical Devices Regulation.
CEO of Medicines Australia, Tim James, said targeted reform is required to further develop the Australian regulatory system, ensuring that it’s adaptive and responsive to changes in business and technology.
“It’s important that we can identify ways to restructure Australia’s regulatory framework so that it is fit-for-purpose and globally competitive,” Mr James said.
Medicines Australia CEO, Tim James, has welcomed the appointment of the Hon Sussan Ley MP as the new Minister for Health.
“I congratulate Minister Ley on her appointment to a portfolio that directly affects the lives of all Australians,” Mr James said.
“This is a critical time for the medicines industry in Australia, and I’ll be working with the Minister and her office to ensure she is fully briefed on our priority issues.”
A new report released today shows the Pharmaceutical Benefits Scheme (PBS) is proving a key driver to reducing overall Government spending on health.
Medicines Australia, CEO, Tim James welcomed the Australian Institute of Health and Welfare (AIHW) report Health Expenditure Australia 2012-13: analysis by sector.
“It’s no surprise that the PBS is one of the main drivers of efficiency in the health system. Even back in September the AIHW reported that total Australian Government health expenditure fell in 2012–13, with the PBS acting as one of the main drivers of that decrease,” Mr James said.
A report released today shows mortality rates from all types of cancer have dropped markedly over the past thirty years, coinciding with a range of ground-breaking new cancer medicines coming into the Australian market.
The Australian Institute of Health and Welfare (AIHW) report, Cancer in Australia in brief 2014, shows that despite an increase in prevalence of various cancers, survival rates have dramatically improved.
Medicines Australia CEO, Tim James, welcomed the report’s findings, which showed the overall mortality rate from cancer is expected to drop by 20 per cent from 209 deaths per 100,000 people in 1982, to 168 deaths per 100,000 people in 2014.